The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.
Participants will be asked to sign a consent and complete a screening visit prior to study entry including the following procedures for this study:
Consent and Screening:
* Laboratory tests to determine baseline health
* Ultrasound to measure kidney size and ensure presence of 2 functioning kidneys
Month 0:
* Study entry kidney MRI (day 0)
* Study entry kidney biopsy (within 30 days of MRI)
* Study entry visit for dispensing 100 mg/daily Canagliflozin medication 3 month supply
Month 3:
* Study visit to dispense remaining 3 months of 100 mg/daily Canagliflozin medication
* Review of systems
Month 6:
* Follow-up kidney MRI
* Follow-up kidney biopsy
Study participants will also be requested to provide blood and urine samples for biobanking purposes. They will also be provided the opportunity to provide a stool sample at two time points, as well as the option to participate in a related study collecting samples to create induced Pluripotent Stem Cells (iPSCs).
Participants will be compensated for their time and loss of work time, additionally, a nominal additional compensation for optional stool and iPSC samples.